BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16 Suppl 1:53-58. [PMID: 21896086 DOI: 10.1111/j.1523-5378.2011.00881.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP. Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:1484-1485; author reply 1486. [PMID: 22582841 DOI: 10.1111/j.1365-2036.2012.05117.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
2 Nazari P, Dowlatabadi-bazaz R, Mofid MR, Pourmand MR, Daryani NE, Faramarzi MA, Sepehrizadeh Z, Shahverdi AR. The Antimicrobial Effects and Metabolomic Footprinting of Carboxyl-Capped Bismuth Nanoparticles Against Helicobacter pylori. Appl Biochem Biotechnol 2014;172:570-9. [DOI: 10.1007/s12010-013-0571-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
3 Tonkic A, Tonkic M, Brnic D, Novak A, Puljiz Z, Simunic M. Time trends of primary antibiotic resistance of Helicobacter pylori isolates in Southern Croatia. Journal of Chemotherapy 2013;24:182-4. [DOI: 10.1179/1973947812y.0000000001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Sung JK. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Yang X, Tan P, Song L, Lu Z. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. American Journal of Therapeutics 2016;23:e1436-41. [DOI: 10.1097/mjt.0000000000000261] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Smith SM. Role of Toll-like receptors in Helicobacter pylori infection and immunity. World J Gastrointest Pathophysiol 2014; 5(3): 133-146 [PMID: 25133016 DOI: 10.4291/wjgp.v5.i3.133] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
7 Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18(40): 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
8 Gasparetto M, Pescarin M, Guariso G. Helicobacter pylori Eradication Therapy: Current Availabilities. ISRN Gastroenterol. 2012;2012:186734. [PMID: 22900197 DOI: 10.5402/2012/186734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
9 Gisbert JP, Calvet X, Ferrándiz J, Mascort J, Alonso-Coello P, Marzo M; Sociedad Española de Medicina de Familia y Comunitaria. [Clinical practice guideline on the management of patients with dyspepsia. Update 2012]. Gastroenterol Hepatol 2012;35:725.e1-38. [PMID: 23186826 DOI: 10.1016/j.gastrohep.2012.05.002] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Lim HC, Lee YJ, An B, Lee SW, Lee YC, Moon BS. Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori. Helicobacter. 2014;19:455-461. [PMID: 25231089 DOI: 10.1111/hel.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
11 Săsăran MO, Meliț LE, Dobru ED. MicroRNA Modulation of Host Immune Response and Inflammation Triggered by Helicobacter pylori. Int J Mol Sci 2021;22:1406. [PMID: 33573346 DOI: 10.3390/ijms22031406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gisbert JP. Rescue Therapy for Helicobacter pylori Infection 2012. Gastroenterol Res Pract. 2012;2012:974594. [PMID: 22536225 DOI: 10.1155/2012/974594] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
13 Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology. 2012;143:55-61.e1; quize e13-4. [PMID: 22484118 DOI: 10.1053/j.gastro.2012.03.043] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
14 Milani M, Sharifi Y, Rahmati-Yamchi M, Somi MH, Akbarzadeh A. Immunology and vaccines and nanovaccines for Helicobacter pylori infection. Expert Rev Vaccines. 2015;14:833-840. [PMID: 25645086 DOI: 10.1586/14760584.2015.1008460] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
15 Ruggiero P. Helicobacter pylori infection: whatʼs new. Current Opinion in Infectious Diseases 2012;25:337-44. [DOI: 10.1097/qco.0b013e3283531f7c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
16 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
17 Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks! J Clin Gastroenterol. 2012;46:259-261. [PMID: 22395061 DOI: 10.1097/mcg.0b013e318247177e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
18 Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori A systematic review and meta-analysis. Scand J Gastroenterol. 2014;49:528-538. [PMID: 24611790 DOI: 10.3109/00365521.2014.887765] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
19 Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi A, Benajah DA. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study. Clin Res Hepatol Gastroenterol. 2013;37:416-421. [PMID: 23168228 DOI: 10.1016/j.clinre.2012.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
20 Latos W, Sieroń-Stołtny K, Kawczyk-Krupka A, Operchalski T, Cieślar G, Kwiatek S, Bugaj AM, Sieroń A. Clinical evaluation of twenty cases of heterotopic gastric mucosa of upper esophagus during five-year observation, using gastroscopy in combination with histopathological and microbiological analysis of biopsies. Contemp Oncol (Pozn) 2013;17:171-5. [PMID: 23788986 DOI: 10.5114/wo.2013.34376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
21 Banga Ndzouboukou JL, Lei Q, Ullah N, Zhang Y, Hao L, Fan X. Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori. Helicobacter 2021;26:e12758. [PMID: 33259676 DOI: 10.1111/hel.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Lee ST, Lee DH, Lim JH, Kim N, Park YS, Shin CM, Jo HJ, Song IS. Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection. Gut Liver. 2015;9:478-485. [PMID: 25071068 DOI: 10.5009/gnl14020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
23 Karczewska E, Klesiewicz K, Skiba I, Wojtas-bonior I, Sito E, Czajecki K, Zwolińska-wcisło M, Budak A. Variability in Prevalence of Helicobacter pylori Strains Resistant to Clarithromycin and Levofloxacin in Southern Poland. Gastroenterology Research and Practice 2012;2012:1-7. [DOI: 10.1155/2012/418010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
25 Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. Helicobacter 2012;17:458-65. [DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
26 Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang L. Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori. Mol Pharm. 2012;9:2677-2685. [PMID: 22827534 DOI: 10.1021/mp300243w] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
27 Meliț LE, Mărginean CO, Mărginean CD, Mărginean MO. The Relationship between Toll-like Receptors and Helicobacter pylori-Related Gastropathies: Still a Controversial Topic. J Immunol Res 2019;2019:8197048. [PMID: 30863783 DOI: 10.1155/2019/8197048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
28 Cammarota G, Sanguinetti M, Gallo A, Posteraro B. Review article: biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012;36:222-30. [DOI: 10.1111/j.1365-2036.2012.05165.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
29 Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 2014;122:941-950. [PMID: 24628732 DOI: 10.1111/apm.12237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
30 Harris SA, Harris EA. Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease. J Alzheimers Dis 2015;48:319-53. [PMID: 26401998 DOI: 10.3233/JAD-142853] [Cited by in Crossref: 125] [Cited by in F6Publishing: 76] [Article Influence: 20.8] [Reference Citation Analysis]
31 Medeiros JA, Pereira MI. The use of probiotics in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:1-5. [PMID: 23222208 DOI: 10.1097/mcg.0b013e3182702dbc] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
32 Nabati F, Mojab F, Habibi-Rezaei M, Bagherzadeh K, Amanlou M, Yousefi B. Large scale screening of commonly used Iranian traditional medicinal plants against urease activity. Daru 2012;20:72. [PMID: 23351780 DOI: 10.1186/2008-2231-20-72] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
33 Mcnicholl AG, Gisbert JP. Commentary: comparators in H. pylori eradication - stating the ethics of statins. Aliment Pharmacol Ther 2012;36:400-1. [DOI: 10.1111/j.1365-2036.2012.05191.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Chang SS, Hu HY. Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens. World J Gastrointest Pharmacol Ther 2015; 6(4): 127-136 [PMID: 26558147 DOI: 10.4292/wjgpt.v6.i4.127] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Seyyedmajidi M, Abbasi L, Seyedmajidi S, Hosseini SA, Ahmadi A, Hajiebrahimi S, Vafaeimanesh J. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori. Caspian J Intern Med 2019;10:211-6. [PMID: 31363400 DOI: 10.22088/cjim.10.2.211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]